1
|
Kuzikov AV, Masamrekh RA, Filippova TA, Tumilovich AM, Strushkevich NV, Gilep AA, Khudoklinova YY, Shumyantseva VV. Bielectrode Strategy for Determination of CYP2E1 Catalytic Activity: Electrodes with Bactosomes and Voltammetric Determination of 6-Hydroxychlorzoxazone. Biomedicines 2024; 12:152. [PMID: 38255257 PMCID: PMC10812958 DOI: 10.3390/biomedicines12010152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Revised: 12/26/2023] [Accepted: 01/05/2024] [Indexed: 01/24/2024] Open
Abstract
We describe a bielectrode system for evaluation of the electrocatalytic activity of cytochrome P450 2E1 (CYP2E1) towards chlorzoxazone. One electrode of the system was employed to immobilize Bactosomes with human CYP2E1, cytochrome P450 reductase (CPR), and cytochrome b5 (cyt b5). The second electrode was used to quantify CYP2E1-produced 6-hydroxychlorzoxazone by its direct electrochemical oxidation, registered using square-wave voltammetry. Using this system, we determined the steady-state kinetic parameters of chlorzoxazone hydroxylation by CYP2E1 of Bactosomes immobilized on the electrode: the maximal reaction rate (Vmax) was 1.64 ± 0.08 min-1, and the Michaelis constant (KM) was 78 ± 9 μM. We studied the electrochemical characteristics of immobilized Bactosomes and have revealed that electron transfer from the electrode occurs both to the flavin prosthetic groups of CPR and the heme iron ions of CYP2E1 and cyt b5. Additionally, it has been demonstrated that CPR has the capacity to activate CYP2E1 electrocatalytic activity towards chlorzoxazone, likely through intermolecular electron transfer from the electrochemically reduced form of CPR to the CYP2E1 heme iron ion.
Collapse
Affiliation(s)
- Alexey V. Kuzikov
- Institute of Biomedical Chemistry, 10, Pogodinskaya Street, 119121 Moscow, Russia; (R.A.M.); (T.A.F.); (A.A.G.); (V.V.S.)
- Department of Biochemistry, Faculty of Biomedicine, Pirogov Russian National Research Medical University, 1, Ostrovityanova Street, 117997 Moscow, Russia;
| | - Rami A. Masamrekh
- Institute of Biomedical Chemistry, 10, Pogodinskaya Street, 119121 Moscow, Russia; (R.A.M.); (T.A.F.); (A.A.G.); (V.V.S.)
- Department of Biochemistry, Faculty of Biomedicine, Pirogov Russian National Research Medical University, 1, Ostrovityanova Street, 117997 Moscow, Russia;
| | - Tatiana A. Filippova
- Institute of Biomedical Chemistry, 10, Pogodinskaya Street, 119121 Moscow, Russia; (R.A.M.); (T.A.F.); (A.A.G.); (V.V.S.)
- Department of Biochemistry, Faculty of Biomedicine, Pirogov Russian National Research Medical University, 1, Ostrovityanova Street, 117997 Moscow, Russia;
| | - Anastasiya M. Tumilovich
- Institute of Bioorganic Chemistry NASB, 5 Building 2, V.F. Kuprevich Street, 220084 Minsk, Belarus; (A.M.T.); (N.V.S.)
| | - Natallia V. Strushkevich
- Institute of Bioorganic Chemistry NASB, 5 Building 2, V.F. Kuprevich Street, 220084 Minsk, Belarus; (A.M.T.); (N.V.S.)
| | - Andrei A. Gilep
- Institute of Biomedical Chemistry, 10, Pogodinskaya Street, 119121 Moscow, Russia; (R.A.M.); (T.A.F.); (A.A.G.); (V.V.S.)
- Institute of Bioorganic Chemistry NASB, 5 Building 2, V.F. Kuprevich Street, 220084 Minsk, Belarus; (A.M.T.); (N.V.S.)
| | - Yulia Yu. Khudoklinova
- Department of Biochemistry, Faculty of Biomedicine, Pirogov Russian National Research Medical University, 1, Ostrovityanova Street, 117997 Moscow, Russia;
| | - Victoria V. Shumyantseva
- Institute of Biomedical Chemistry, 10, Pogodinskaya Street, 119121 Moscow, Russia; (R.A.M.); (T.A.F.); (A.A.G.); (V.V.S.)
- Department of Biochemistry, Faculty of Biomedicine, Pirogov Russian National Research Medical University, 1, Ostrovityanova Street, 117997 Moscow, Russia;
| |
Collapse
|
2
|
Vrba J, Papoušková B, Roubalová L, Zatloukalová M, Biedermann D, Křen V, Valentová K, Ulrichová J, Vacek J. Metabolism of flavonolignans in human hepatocytes. J Pharm Biomed Anal 2018; 152:94-101. [PMID: 29414024 DOI: 10.1016/j.jpba.2018.01.048] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Revised: 01/22/2018] [Accepted: 01/23/2018] [Indexed: 12/11/2022]
Abstract
This study examined the in vitro biotransformation of eight structurally related flavonolignans, namely silybin, 2,3-dehydrosilybin, silychristin, 2,3-dehydrosilychristin, silydianin, 2,3-dehydrosilydianin, isosilybin A and isosilybin B. The metabolic transformations were performed using primary cultures of human hepatocytes and recombinant human cytochromes P450 (CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4). The metabolites produced were analyzed by ultra-performance liquid chromatography coupled with tandem mass spectrometry. We found that each of the tested compounds was metabolized in vitro by one or more CYP enzymes, which catalyzed O-demethylation, hydroxylation, hydrogenation and dehydrogenation reactions. In human hepatocytes, silybin, 2,3-dehydrosilybin, silychristin, 2,3-dehydrosilychristin, and isosilybins A and B were directly conjugated by sulfation or glucuronidation. Moreover, isosilybin A was also converted to a methyl derivative, while isosilybin B was hydroxylated and methylated. Silydianin and 2,3-dehydrosilydianin were found to undergo hydrogenation and/or glucuronidation. In addition, 2,3-dehydrosilydianin was found to be metabolically the least stable flavonolignan in human hepatocytes, and its main metabolite was a cleavage product corresponding to a loss of CO. We conclude that the hepatic biotransformation of flavonolignans primarily involves the phase II conjugation reactions, however in some cases the phase I reactions may also occur. These results are highly relevant for research focused on flavonolignan metabolism and pharmacology.
Collapse
Affiliation(s)
- Jiří Vrba
- Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 3, Olomouc 77515, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 3, Olomouc 77515, Czech Republic
| | - Barbora Papoušková
- Regional Centre of Advanced Technologies and Materials, Department of Analytical Chemistry, Faculty of Science, Palacký University, 17. listopadu 12, Olomouc 77146, Czech Republic
| | - Lenka Roubalová
- Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 3, Olomouc 77515, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 3, Olomouc 77515, Czech Republic
| | - Martina Zatloukalová
- Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 3, Olomouc 77515, Czech Republic
| | - David Biedermann
- Institute of Microbiology of the Czech Academy of Sciences, Laboratory of Biotransformation, Vídeňská 1083, Prague 14220, Czech Republic
| | - Vladimír Křen
- Institute of Microbiology of the Czech Academy of Sciences, Laboratory of Biotransformation, Vídeňská 1083, Prague 14220, Czech Republic
| | - Kateřina Valentová
- Institute of Microbiology of the Czech Academy of Sciences, Laboratory of Biotransformation, Vídeňská 1083, Prague 14220, Czech Republic
| | - Jitka Ulrichová
- Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 3, Olomouc 77515, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 3, Olomouc 77515, Czech Republic
| | - Jan Vacek
- Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 3, Olomouc 77515, Czech Republic.
| |
Collapse
|